Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 7/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575115 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL2400336 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL6040158 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL6570212 | 0.92 | SLC6A11 (0.47) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL992028 | 0.91 | SLC6A11 (0.50) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2490410 | 0.91 | SLC6A11 (0.50) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2288433 | 0.90 | SLC6A11 (0.43) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL24207815 | 0.87 | KIF11 (0.55) | SLC6A1KIF11TK2MEN1CYP1A2 | |
| SCHEMBL3485522 | 0.87 | KIF11 (0.55) | SLC6A1KIF11TK2MEN1CYP1A2 | |
| SCHEMBL24207971 | 0.87 | KIF11 (0.55) | SLC6A1KIF11TK2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071737-B2 | Nucleic acid ligand complexes | Glead Sciences, Inc. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110212030-A1 | Nucleic Acid Ligand Complexes | GILEAD SCIENCES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| EP-2168973-A1 | Nucleic acid ligand complexes | Gilead Sciences, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-0824541-B1 | NUCLEIC ACID LIGAND COMPLEXES | GILEAD SCIENCES INC (US) | 2009-12-16 | — | — | EP | disclosed |
| EP-0824541-A4 | NUCLEIC ACID LIGAND COMPLEXES | GILEAD SCIENCES INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20050164974-A1 | Nucleic acid ligand complexes | THE REGENTS OF THE UNIVERSITY OF COLORADO, SUCCESSOR IN INTEREST TO UNIVERSITY RESEARCH CORPORATION AND/OR UNIVERSITY LICENSE EQUITY HOLDINGS, INC. | 2005-07-28 | — | — | US | disclosed |
| US-6825331-B2 | DIAGNOSTIC HYBRIDIZATION PROBES; BIOCHEMICAL CONJUGATION | ISIS PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030125263-A1 | Nucleic acid ligand complexes | GILEAD SCIENCES, INC. (US) | 2003-07-03 | — | — | US | disclosed |
| US-20030113769-A1 | Aminooxy functionalized oligomers, oligomer arrays and methods of using them | IONIS PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6576752-B1 | Oligonucleotide comprising a plurality of nucleotide units of given structure; useful for diagnostic, therapeutic and investigative purposes | ISIS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-6465188-B1 | PARTITIONING, GENETIC REPLICATION; SELEX | GILEAD SCIENCES, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6147204-A | COMPLEX FOR TARGETING THERAPEUTIC OR DIAGNOSTIC AGENTS TO PREFERENTIAL BIOLOGICAL TARGET | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6011020-A | THERAPEUTIC OR DIAGNOSTIC COMPLEX COMPRISED OF A NUCLEIC ACID LIGAND AND A POLYETHYLENE GLYCOL (PEG), WHEREIN SAID NUCLEIC ACID LIGAND IS COVALENTLY LINKED TO SAID PEG | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0824541-A1 | NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996034876-A1 | NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212030-A1 | Nucleic Acid Ligand Complexes | TLR9, SNRPE, HAVCR2 | SLC6A11 3991/4885SLC6A1 4107/4885KIF11 3006/4885 |
| US-20050164974-A1 | Nucleic acid ligand complexes | TLR9, SNRPE, HAVCR2 | SLC6A11 3991/4885SLC6A1 4107/4885KIF11 3006/4885 |
| US-20030125263-A1 | Nucleic acid ligand complexes | TLR9, SNRPE, HAVCR2 | SLC6A11 3991/4885SLC6A1 4107/4885KIF11 3006/4885 |
| US-20030113769-A1 | Aminooxy functionalized oligomers, oligomer arrays and methods of using them | RNGTT, RNMT, DCLRE1B | SLC6A11 3089/4885SLC6A1 3878/4885KIF11 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.